Kaye Scholer Fends Off Challenge to Pfizer Cancer Drug Patents

, The Litigation Daily

   |0 Comments

Generic drug maker Mylan applied to the FDA to market its own version of the cancer drug Tarceva in 2009, betting that its lawyers at Wiley Rein could fend off infringement claims by asserting that Pfizer's patents for the drug didn't pass muster. The company lost that bet on Tuesday, when lawyers at Kaye Scholer convinced a Delaware judge that the patents are valid.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202551419018

Thank you!

This article's comments will be reviewed.